Synthetic Biologics, Inc (SYN) financial statements (2021 and earlier)

Company profile

Business Address 9605 MEDICAL CENTER DRIVE
ROCKVILLE, MD 20850
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6152917192118
Cash and cash equivalents6152917192118
Receivables00 0   
Prepaid expense10001 0
Other current assets    0102
Other undisclosed current assets11112 (0)
Total current assets:8163018223019
Noncurrent Assets
Operating lease, right-of-use asset00
Property, plant and equipment0011100
Other undisclosed noncurrent assets0000000
Total noncurrent assets:0111110
TOTAL ASSETS:8173019223119
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3536553
Accounts payable1212241
Accrued liabilities1212301
Employee-related liabilities1112001
Interest and dividends payable   0   
Debt 0     
Deferred rent credit  0
Deferred revenue and credits000 
Other undisclosed current liabilities0  415117
Total current liabilities:35310201610
Noncurrent Liabilities
Long-term debt and lease obligation00     
Operating lease, liability00
Liabilities, other than long-term debt  0000 
Deferred revenue and credits000 
Deferred rent credit  0
Other undisclosed noncurrent liabilities(0)      
Total noncurrent liabilities:000000 
Total liabilities:36410201610
Temporary equity, carrying amount131312    
Stockholders' equity
Stockholders' equity attributable to parent, including:(5)217(1)41610
Preferred stock2      
Common stock0000000
Additional paid in capital241233231193176161111
Accumulated deficit(248)(236)(219)(194)(172)(145)(101)
Other undisclosed stockholders' equity attributable to parent 56    
Stockholders' equity attributable to noncontrolling interest(3)(3)(3)(2)(2)(1) 
Total stockholders' equity:(8)(1)14(3)21510
Other undisclosed liabilities and equity   12   
TOTAL LIABILITIES AND EQUITY:8173019223119

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(10)(16)(18)(26)(39)(41)(21)
Operating loss:(10)(16)(18)(26)(39)(41)(21)
Nonoperating income (expense)0041111(4)1
Investment income, nonoperating0000000
Loss from continuing operations before income taxes:(10)(15)(13)(15)(28)(45)(20)
Income tax benefit3     8
Loss before gain (loss) on sale of properties:(7)(15)(13)(15)(28)(45)(12)
Other undisclosed net loss(3)     (8)
Net loss:(10)(15)(13)(15)(28)(45)(20)
Net income attributable to noncontrolling interest000011 
Net loss attributable to parent:(10)(15)(13)(15)(27)(44)(20)
Preferred stock dividends and other adjustments(0)(0)(0)(7)   
Other undisclosed net loss available to common stockholders, basic(2)(1)(12)    
Net loss available to common stockholders, diluted:(13)(16)(25)(22)(27)(44)(20)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(10)(15)(13)(15)(28)(45)(20)
Comprehensive loss:(10)(15)(13)(15)(28)(45)(20)
Comprehensive income, net of tax, attributable to noncontrolling interest000011 
Comprehensive loss, net of tax, attributable to parent:(10)(15)(13)(15)(27)(44)(20)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: